Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles
Clin. transl. oncol. (Print)
; 14(6): 413-422, jun. 2012.
Artigo
em Inglês
| IBECS
| ID: ibc-126809
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Chemotherapy-induced nausea and vomiting (CINV) is a major determinant of quality of life in cancer patients. In addition, the perceptions that oncology professionals have about CINV quite often do not coincide with reality. Antineoplastic agents and their combinations can be categorised according to their emetogenic level, and this categorisation is helpful for classifying the severity of CINV and treating it. All CINV treatment guidelines emphasise the need to administer prophylaxis to patients who receive highly or moderately emetogenic chemotherapy. With the introduction of NK1 receptor antagonists, the control of acute and delayed CINV after highly or moderately emetogenic chemotherapy schedules has improved in the great majority of patients. NK1 receptor antagonists have been demonstrated to improve the control of CINV in all risk subgroups of patients (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Vômito
/
Náusea
/
Antineoplásicos
Tipo de estudo:
Guia de prática clínica
Aspecto:
Preferência do paciente
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2012
Tipo de documento:
Artigo
Instituição/País de afiliação:
Corporació Sanitaria I Universitaria Parc Taulí/Spain
/
Fundación Hospital Alcorcón/Spain
/
Hospital Juan Ramón Jiménez/Spain
/
Hospital La Princesa/Spain
/
Hospital Universitario A Coruña/Spain
/
Hospital Universitario Central de Asturias/Spain
/
Hospital Universitario Virgen del Rocío/Spain
/
Hospital de la Santa Creu I Sant Pau/Spain
/
Hospital del Mar/Spain